To Study the Effect of Polymorphisms in Fas Ligand Gene Promoter Region (rs 763110) and Fas gene (rs1800682) on Platinum-Based regimens used in treatment of malignant pleural mesothelioma (MPM)
|First Received Date||October 11, 2014|
|Last Changed Date||December 30, 2017|
|Start Date||April 2014|
|Actual Primary Completion Date||June 2016|
|Primary Outcome Measures||
response rate [Time Frame: After 6 cycles of chemotherapy (each cycle is 21 days )]
|Secondary Outcome Measures||
progression free survival (PFS) [Time Frame: one year]
overall survival (OS) [Time Frame: one year]
estimation of treatment related toxicity [Time Frame: during the chemotherapy period, average duration 4 months]
|Study Arms / Comparison Groups||0 / 2|
This study tries to find a correlation between single nucleotide polymorphisms (SNP) found in promoter region of Fas Ligand gene (rs 763110) and Fas (rs1800682) and clinical outcome on patients with MPM treated with platinum-Based agents as first line. the patients will have one of three following genotypes : Thymine/Thymine, Thymine/Cytosine or Cytosine/Cytosine (for Fas ligand polymorphism) and Adenine/Adenine, Adenine/Guanine or Guanine/Guanine ( for Fas polymorphism).
|Ages||18 Years - N/A|
|Accepts Healthy Volunteers||No|
- Patients with histologically confirmed Malignant Pleural Mesothelioma
- Age of 18 years or more.
- first-line chemotherapy with platinum-Based agents
- history of prior malignancy.
- pregnancy or lactation or any other reason preventing him from taking platinum-Based chemotherapy (AST more than 2.5* Upper Limit of Normal or Serum bilirubin more than 1.5* Upper Limit of Normal)
|Responsible Party||Principal Investigator|
|Sponsor||Ain Shams University|
|Verification Date||December 2017|